RECURSION PHARMACEUTICALS, INC. (RXRX) Form 10-Q — Nov 2, 2026
Recursion Pharmaceuticals reported Q3 2026 revenue of $18.6 million, up more than 100% year over year, driven by a $10.0 million Sanofi milestone after Sanofi optioned the first development candidate from their collaboration. Net loss narrowed 27% to $119.0 million from $162.3 million a year ago, with cash, cash equivalents and restricted cash of $561.5 million at quarter end — before netting an additional ~$187.2 million from an October 2026 underwritten offering of 61.5 million shares.
Key figures
- Revenue
- 18552000
- Total Assets
- 1221712000
- Cash Position
- 561530000
- Shares Outstanding
- 622759259
- Q3 ga expense
- 32561000
- Q3 rnd expense
- 99122000
- Nine month revenue
- 32694000
- Accumulated deficit
- 2443547000
- Sanofi milestone q3
- 10000000
- Atm net proceeds ytd
- 85515000
- Atm remaining capacity
- 213300000
- Net loss yoy improvement pct
- 27
- October 2026 offering shares
- 61500000
- October 2026 offering net proceeds
- 187200000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.